ASSOCIATION BETWEEN USE OF ANTI-HYPERTENSIVE DRUGS AND RISK OF HEPATOCELLULAR CARCINOMA (HCC) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) PATIENTS WITH CIRRHOSIS

被引：0
|
作者：
Elhariri, Ahmed [1 ]
Hassan, Manal [2 ]
ELsheikh, Mazen [1 ]
El Sabagh, Ahmed [3 ]
Ibrahim, Mohamad Ali [1 ]
Bhongade, Megha [1 ]
Albarouki, Sali [1 ]
Nayak, Anish [1 ]
Karouni, Youseph [1 ]
Jalal, Prasun [1 ]
机构：
[1] Baylor Coll Med, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Washington Hosp Ctr, Medstar Georgetown, Washington, DC USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1131
引用
收藏
页码：S859 / S860
页数：2
相关论文
共 50 条
  • [1] Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
    Nakamura, Toru
    Masuda, Atsutaka
    Nakano, Dan
    Amano, Keisuke
    Sano, Tomoya
    Nakano, Masahito
    Kawaguchi, Takumi
    CELLS, 2025, 14 (06)
  • [2] Hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease (MASLD): multicenter study comparing patients with or without underlying cirrhosis
    Vitellius, Carole
    Desjonqueres, Elvire
    Lequoy, Marie
    Amaddeo, Giuliana
    Fouchard, Isabelle
    Gisele, NKontchou
    Canivet, Clemence M.
    Ziol, Marianne
    Regnault, Helene
    Lannes, Adrien
    Oberti, Frederic
    Boursier, Jerome
    Ganne-Carrie, Nathalie
    JOURNAL OF HEPATOLOGY, 2024, 80 : S456 - S456
  • [3] Risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
    Liew, Ian Yang
    Phua, Hwee Pin
    Lim, Wei Yen
    Chow, Angela
    Loo, Xiu Ying
    Sim, Kevin
    Lee, Eng Sing
    Yew, Kuo Chao
    JOURNAL OF HEPATOLOGY, 2024, 80 : S497 - S498
  • [4] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    JAMA NETWORK OPEN, 2024, 7 (07) : e2421019
  • [5] Effect of antidiabetics on the risk of hepatocellular carcinoma in patients with diabetes and metabolic dysfunction-associated steatotic liver disease
    Lee, Han Ah
    Kim, Hwi Young
    Seo, Yeon Seok
    Ahn, Sang Hoon
    Kim, Seung Up
    JOURNAL OF HEPATOLOGY, 2024, 80 : S481 - S481
  • [6] Risk Stratification of Patients with Metabolic Dysfunction-associated Steatotic Liver Disease Steatohepatitis, Fibrosis, and Hepatocellular Carcinoma
    El-Kassas, Mohamed
    Othman, Heba A.
    Elbadry, Mohamed
    Alswat, Khalid
    Yilmaz, Yusuf
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (01)
  • [7] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [8] CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS WITH CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN SWEDEN
    Shang, Ying
    Zhang, Xiao
    Fernandes, Gail
    Melaragno, Matthew
    Engel, Samuel
    Vessby, Johan
    Ekstedt, Mattias
    Hagstrom, Hannes
    HEPATOLOGY, 2024, 80 : S821 - S822
  • [9] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
    Kim, Gi-Ae
    Jeong, Seogsong
    Jang, Heejoon
    Lee, Dong Hyeon
    Joo, Sae Kyung
    Kim, Won
    LIVER CANCER, 2024, 13 (04) : 426 - 437
  • [10] Genome-wide Association Study on Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
    Darlay, Rebecca
    Zatorska, Michalina
    Worthington, Sarah
    Anstee, Quentin M.
    Daly, Ann K.
    Cordell, Heather J.
    GENETIC EPIDEMIOLOGY, 2024, 48 (07) : 352 - 352
12345